Don’t invest unless you’re prepared to lose all the money you invest. This is a high‑risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.

Screenshot 2024 02 26 at 10 43 38

ArkVax launches new website

Portfolio company ArkVax recently announced their new website.

ArkVax is a spin-out from the London School of Hygiene and Tropical Medicine. They specialise in developing glycoconjugate vaccines and aim to revolutionise animal vaccinology by creating safe, effective, low-cost vaccines to address the unmet need for suitable and effective animal vaccinations.

ArkVax’s glycan-based solutions have the potential to disrupt the antibacterial vaccine space and transform animal health by offering greater potency and broader protection than current vaccines. Their solution also has the potential to combat antimicrobial resistance in animals, but also humans by conferring protection from zoonotic diseases.

You can now find out more by visiting their website: